[{"id":"6b981973-5044-48d8-8609-e2a64de918ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT02392611","created_at":"2021-01-18T11:24:33.676Z","updated_at":"2024-07-02T16:36:36.790Z","phase":"Phase 1","brief_title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT02392611","lead_sponsor":"Gilead Sciences","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • exemestane • alobresib (GS-5829)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 03/16/2015","start_date":" 03/16/2015","primary_txt":" Primary completion: 10/11/2017","primary_completion_date":" 10/11/2017","study_txt":" Completion: 10/11/2017","study_completion_date":" 10/11/2017","last_update_posted":"2020-12-29"}]